OrthoPediatrics

OrthoPediatrics Corp. is an orthopedic company, which engages in the design, development, and marketing of anatomically appropriate implants and devices for children with orthopedic conditions. It offers products relating to trauma and deformity, scoliosis, and sports medicine and other procedures. The company was founded by Erin Springer Yount and Nick A. Deeter in August 2006 and is headquartered in Warsaw, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OrthoPediatrics achieves record revenue growth and eyes international expansion

OrthoPediatrics delivered strong financial performance in 2022, achieving profitability and record revenue growth despite challenges. With a focus on new product launches, international expansion, and surgeon training, the company is well-positioned for continued growth and profitability.

OrthoPediatrics reports robust Q1 earnings, eyes international growth opportunities

OrthoPediatrics had a strong Q1 2023, with increased revenue guidance for the full year. The company remains cautiously optimistic due to staffing dynamics. Focus on new product development, acquisitions, and addressing digital needs of children's hospitals highlight growth strategies.

OrthoPediatrics achieves record Q2 performance amidst growth challenges

OrthoPediatrics delivered strong Q2 results with record child assistance and revenue growth, driven by trauma, deformity, and international segments.
While facing challenges like atypical growth patterns and delays in product launches, the company is well-positioned to capitalize on opportunities in enabling technologies and international expansion.
The focus on long-term growth drivers and strategic acquisitions underscores OrthoPediatrics' commitment to sustainable growth and innovation in pediatric orthopedics.
Overall, OrthoPediatrics' performance highlights operational efficiency, market demand, and a clear path for future growth and expansion.

OrthoPediatrics achieves record revenue in Q3 2023, eyes continued growth

OrthoPediatrics reported strong financial performance in Q3 2023, with record revenue and EBITDA, positioning the company for future growth. Despite challenges in certain segments, opportunities in new product launches, international expansion, and surgeon training initiatives offer avenues for continued success. The company's positive outlook and robust pipeline indicate a promising trajectory for OrthoPediatrics.

OrthoPediatrics achieves record revenue and EBITDA, eyes international expansion

OrthoPediatrics delivered strong financial performance in 2023, setting revenue and EBITDA records. The company's strategic focus on sustainable growth, profitability, and diversification positions it well for future success.

OrthoPediatrics reports robust Q1 growth, raises full-year revenue guidance

OrthoPediatrics demonstrated strong performance in Q1 2024 with significant growth in patients helped, revenue, and key business segments. While facing challenges such as an EBITDA loss and increased expenses, the company's focus on growth, new product launches, and financial targets positions it well for the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WARSAW, Ind., Dec. 29, 2020 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, today announced the first surgery in the United Kingdom utilizing the new Pediatric Nailing Platform | FEMUR (“PNP|FEMUR”).

OrthoPediatrics Corp. Announces First PNP|FEMUR Case Performed in the United Kingdom

Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In OrthoPediatrics Corporation To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - December 24, 2020) - Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential violations of the federal securities laws against OrthoPediatrics Corporation ("OrthoPediatrics" or the "Company") (NASDAQ: KIDS).If you suffered losses exceeding $50,000 investing in OrthoPediatrics Corporation securities and would like to discuss your legal rights, click here: www.faruqilaw.com/KIDS or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or...

OrthoPediatrics Corporation Class Action Reminder

LOS ANGELES--(BUSINESS WIRE)---- $KIDS #KIDS--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against OrthoPediatrics Corp.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against OrthoPediatrics Corp. and Encourages Investors with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $KIDS #KIDS--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against OrthoPediatrics Corp.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against OrthoPediatrics Corp. and Encourages Investors with Losses of $100,000 to Contact the Firm

WARSAW, Ind., Dec. 21, 2020 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its expansion into the U.K. commercial market with the approval and launch of two innovative surgical systems that can provide meaningful advances over existing products.

OrthoPediatrics Corp. Announces International Expansion in the United Kingdom

Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In OrthoPediatrics Corporation To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - December 20, 2020) - Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential violations of the federal securities laws against OrthoPediatrics Corporation ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS).If you suffered losses exceeding $50,000 investing in OrthoPediatrics Corporation securities and would like to discuss your legal rights, click here: www.faruqilaw.com/KIDS or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330...

Orthopediatrics Corporation Deadline Alert

NEW YORK, Dec. 20, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (NASDAQ: KIDS).   Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of OrthoPediatrics Corp. - KIDS

Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In OrthoPediatrics Corporation To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - December 19, 2020) -  Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential violations of the federal securities laws against OrthoPediatrics Corporation ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS).If you suffered losses exceeding $50,000 investing in OrthoPediatrics Corporation securities and would like to discuss your legal rights, click here: www.faruqilaw.com/KIDS or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330...

OrthoPediatrics Corporation Update

SAN FRANCISCO, Dec. 15, 2020 /PRNewswire/ -- Hagens Berman urges OrthoPediatrics Corp. (NASDAQ: KIDS) investors to submit their losses now. The firm is investigating possible securities law violations. Visit: www.hbsslaw.com/investor-fraud/KIDS Contact An Attorney Now: KIDS@hbsslaw.com...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates OrthoPediatrics (KIDS) Fraud Investigation in Light of New Culper Report, Encourages Investors to Contact Its Attorneys Now

Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In OrthoPediatrics Corporation To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - December 13, 2020) - Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential violations of the federal securities laws against OrthoPediatrics Corporation ("OrthoPediatrics" or the "Company") (NASDAQ: KIDS).If you suffered losses exceeding $50,000 investing in OrthoPediatrics Corporation securities and would like to discuss your legal rights, click here: www.faruqilaw.com/KIDS or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or...

Orthopediatrics Corporation Lead Plaintiff Deadline Alert

San Francisco, California--(Newsfile Corp. - December 10, 2020) - Hagens Berman urges OrthoPediatrics Corp. (NASDAQ: KIDS) investors to submit their losses now. The firm is investigating possible securities law violations.Visit: www.hbsslaw.com/investor-fraud/KIDS Contact An Attorney Now: KIDS@hbsslaw.com 844-916-0895OrthoPediatrics Corp. (KIDS) Investigation:The investigation centers on whether OrthoPediatrics artificially inflated reported revenues by engaging in an illegal channel stuffing scheme. In past quarters, OrthoPediatrics tout

KIDS INVESTIGATION: Hagens Berman, National Trial Attorneys, Encourages OrthoPediatrics (KIDS) Investors to Contact Its Attorneys Now, Firm Investigating Possible Securities Fraud

San Francisco, California--(Newsfile Corp. - December 8, 2020) - Hagens Berman urges OrthoPediatrics Corp. (NASDAQ: KIDS) investors to submit their losses now. The firm is investigating possible securities law violations.Visit: www.hbsslaw.com/investor-fraud/KIDS Contact An Attorney Now: KIDS@hbsslaw.com 844-916-0895OrthoPediatrics Corp. (KIDS) Investigation:The investigation centers on whether OrthoPediatrics artificially inflated reported revenues by engaging in an illegal channel stuffing scheme. In past quarters,

KIDS SECURITIES FRAUD INVESTIGATION: Hagens Berman, National Trial Attorneys, Encourages OrthoPediatrics (KIDS) Investors to Contact Its Attorneys Now, Firm Investigating Possible Securities Fraud

SAN FRANCISCO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Hagens Berman urges OrthoPediatrics Corp. (N ASDAQ : K IDS ) investors to submit their losses now . The firm is investigating possible securities law violations.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages OrthoPediatrics (KIDS) Investors to Contact Its Attorneys Now, Firm Investigating Possible Securities Fraud

PHILADELPHIA, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. is investigating claims on behalf of investors of OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (NASDAQ: KIDS) to determine whether the Company engaged in securities fraud or other unlawful business practices.

SHAREHOLDER ALERT: Investors of OrthoPediatrics Who Suffered Losses Greater Than $50,000 Are Encouraged To Contact Kehoe Law Firm, P.C.

OrthoPediatrics Corp. (KIDS) CEO Mark Throdahl on Q3 2020 Results - Earnings Call Transcript

Record Sales Drive Significant Improvement in EBITDA Record Sales Drive Significant Improvement in EBITDA

OrthoPediatrics Corp. Reports Third Quarter 2020 Financial Results

TAMPA, Fla.--(BUSINESS WIRE)--Telos Partners LLC, a subsidiary of OrthoPediatrics Corp. (NASDAQ: KIDS) specializing in the strategic delivery of regulatory, reimbursement and clinician adoption services to the musculoskeletal and wound care industries, is pleased to announce the addition of Erik Waldorff, PhD in the position of Director, Science & Innovation. In this capacity, he will lead the Telos scientific services to lay the foundations of evidence necessary to meet medical device and

Telos Partners LLC Announces the Addition of Erik Waldorff, PhD as Director of Science & Innovation to Fortify Its Expertise in the Musculoskeletal Device and Biotechnology Industry

WARSAW, Ind., Oct. 29, 2020 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Mark Throdahl, Chief Executive Officer, Fred Hite, Chief Operating Officer and Chief Financial Officer, and Dave Bailey, President, are scheduled to participate at three upcoming virtual investor conferences in November.

OrthoPediatrics Corp. to Present at Four Upcoming Investor Conferences in November and December

OrthoPediatrics (KIDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: OrthoPediatrics (KIDS) Q3 Earnings Expected to Decline

Conference Call to Discuss Results on November 5, 2020 at 8:00 a.m. ET Conference Call to Discuss Results on November 5, 2020 at 8:00 a.m. ET

OrthoPediatrics Corp. to Report Third Quarter 2020 Financial Results on November 4, 2020

WARSAW, Ind., Oct. 08, 2020 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its continued support for the 3rd Annual PediOrtho WEST Resident Education Course, which will take place October 16-17 at Shriners Hospitals for Children in Sacramento, California.

OrthoPediatrics Corp. to Support the 3rd Annual PediOrtho WEST Resident Education Course in October 2020

TAMPA, Fla.--(BUSINESS WIRE)--Telos Partners LLC, a subsidiary of OrthoPediatrics Corp.

Telos Partners LLC Appoints Jason Inzana, PhD to General Manager in Next Phase of Growth Strategy

WARSAW, Ind., Sept.  09, 2020  (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its continued support for the Scoliosis Research Society (“SRS”), including the Company’s Gold Level sponsorship for the 55th Annual Meeting & Course taking place virtually on September 9-13. The Company will also continue its support as a Platinum Level Sponsor for the 74th Annual Meeting of the American Academy for Cerebral Palsy and Developmental Medicine (“AACPDM”), which will take place virtually on September 23-26.

OrthoPediatrics Corp. to Sponsor Two Medical Meetings in September 2020

WARSAW, Ind., Sept.  08, 2020  (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Mark Throdahl, Chief Executive Officer, Fred Hite, Chief Operating Officer and Chief Financial Officer, and Dave Bailey, President, are scheduled to participate in the Morgan Stanley 18th Annual Global Healthcare Conference on Tuesday, September 15, 2020.

OrthoPediatrics Corp. to Participate in the Morgan Stanley 18th Annual Global Healthcare Conference

WARSAW, Ind., Sept.  03, 2020  (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced completion of the 1,000th surgery utilizing its Pediatric Nailing Platform | FEMUR (“PNP | FEMUR”), the first system specifically designed and developed to address the unique pediatric anatomies when treating femoral fractures and deformity correction procedures.

OrthoPediatrics Corp. Announces 1,000th Procedure Utilizing its Innovative Pediatric Nailing Platform | FEMUR (“PNP | FEMUR”) System, the First Pediatric-Specific Solution Optimized to Treat Fractures and Deformities

News for OrthoPediatrics Stock (KIDS)